VXRT Material Contracts

Vaxart, Inc. Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

2026-08-06: Form 10-Q; Exhibit 10.6; Description Modification No. 7, dated June 19, 2026, to the ATI-RRPV Project Award Agreement No. 001, dated June 13, 2024, between Vaxart Biosciences Inc. and Advanced Technology International (RRPV Consortium Management Firm)..
2026-07-02: Form 8-K; Exhibit 10.1; Description COOPERATION AGREEMENT, DATED JULY 1, 2026.
2026-05-07: Form 10-Q; Exhibit 10.1; Description Non-Employee Director Compensation Program, effective as of March 10, 2026.
2026-04-17: Form 8-K; Exhibit 10.2; Description Registration Rights Agreement, dated April 16, 2026, between Vaxart, Inc. and Lincoln Park Capital Fund, LLC.

Filed	Form	Exhibit	Description
2026-08-06	10-Q	10.6	Modification No. 7, dated June 19, 2026, to the ATI-RRPV Project Award Agreement No. 001, dated June 13, 2024, between Vaxart Biosciences Inc. and Advanced Technology International (RRPV Consortium Management Firm).
2026-07-02	8-K	10.1	COOPERATION AGREEMENT, DATED JULY 1, 2026
2026-05-07	10-Q	10.1	Non-Employee Director Compensation Program, effective as of March 10, 2026
2026-04-17	8-K	10.2	Registration Rights Agreement, dated April 16, 2026, between Vaxart, Inc. and Lincoln Park Capital Fund, LLC
2026-04-17	8-K	10.1	Purchase Agreement, dated April 16, 2026, between Vaxart, Inc. and Lincoln Park Capital Fund, LLC
2026-03-13	10-K	10.57	Lease Termination Agreement, dated December 18, 2025, by and between Vaxart, Inc. and Britannia Pointe Grand Limited Partnership.
2025-11-13	10-Q	10.2	Securities Purchase Agreement, dated November 4, 2025, between Vaxart, Inc. and Dynavax Technologies Corporation.
2025-11-13	10-Q	10.1	Exclusive License and Collaboration Agreement, dated November 4, 2025, between Vaxart, Inc. and Dynavax Technologies Corporation.
2025-08-13	10-Q	10.1	Offer Letter, dated as of April 18, 2025, between Vaxart, Inc. and Jeroen Grasman.
2025-03-20	10-K	10.53	Modification No. 4, dated December 20, 2024, to the ATI-RRPV Project Award Agreement No. 001, dated June 13, 2024, between Vaxart Biosciences Inc. and Advanced Technology International (RRPV Consortium Management Firm)
2025-02-10	8-K	10.1	Modification No. 5, dated February 7, 2025, to the ATI-RRPV Project Award Agreement No. 001, dated June 13, 2024, between the Company and Advanced Technology International.
2024-11-13	10-Q	10.3	Modification No. 3, dated September 27, 2024, to the ATI-RRPV Project Award Agreement No. 001, dated June 13, 2024, between Vaxart Biosciences Inc. and Advanced Technology International (RRPV Consortium Management Firm)
2024-08-08	10-Q	10.3	ATI-RRPV Project Award Agreement No. 001, dated June 13, 2024, between Vaxart Biosciences Inc. and Advanced Technology International (RRPV Consortium Management Firm)
2024-08-08	10-Q	10.2	ATI-RRPV Base Agreement, dated May 6, 2024, between Vaxart Biosciences Inc. and Advanced Technology International (RRPV Consortium Management Firm)
2024-08-08	10-Q	10.1	EXHIBIT 10.1 DIRECTOR COMPENSATION PROGRAM
2024-06-13	8-K	10.2	2022 Employee Stock Purchase Plan.
2024-06-13	8-K	10.1	2019 Equity Incentive Plan.
2024-03-14	10-K	10.59	ASPR-BARDA Award/Contract, dated January 12, 2024, between Vaxart, Inc. and the U.S. Government through the Department of Health and Human Services
2024-03-06	8-K	10.1	Letter Agreement, between Vaxart, Inc. and Steven Lo.
2024-02-29	8-K	10.3	Form of Stock Option Grant Notice and Stock Option Agreement.
2024-02-29	8-K	10.2	Form of Restricted Stock Unit Award Grant Notice and Award Agreement.
2024-02-29	8-K	10.1	Vaxart, Inc. 2024 Inducement Award Plan.
2024-02-02	8-K/A	10.1	Separation Agreement, dated January 31, 2024, by and between Vaxart, Inc. and Andrei Floroiu.
2024-01-16	8-K	10.1	Securities Purchase Agreement, dated January 16, 2024, by and between Vaxart, Inc. and RA Capital Healthcare Fund, L.P.
2024-01-16	8-K	10.1	Letter Agreement, dated January 16, 2024, between Vaxart, Inc. and Michael J. Finney.
2023-05-04	10-Q	10.2	Amendment to the Vaxart, Inc. Severance Benefit Plan dated May 2, 2023
2023-05-04	10-Q	10.1	Amendment to Letter Agreement dated May 2, 2023 between Andrei Floroiu and Vaxart, Inc.
2023-03-15	10-K	10.53	Offer Letter, dated December 5, 2022, by and between the Company and Phillip Lee
2022-08-08	10-Q	10.4	Pre-Challenge Study Services Agreement dated June 29, 2022, between the Company and hVIVO Services Limited
2022-08-05	8-K/A	10.2	2022 Employee Stock Purchase Plan.
2022-08-05	8-K/A	10.1	2019 Equity Incentive Plan.
2022-05-11	8-K	10.2	Consulting Services Agreement between the Company and Ms. Echerd, effective as of May 11, 2022.
2022-05-11	8-K	10.1	Confidential Consulting Agreement between the Company and FLG Partners, LLC, effective as of April 20, 2022.
2022-05-09	10-Q	10.2	Non-Employee Director Compensation Program, effective as of April 1, 2022
2022-02-24	10-K	10.46	Offer letter, dated January 18, 2022, by and between the Company and Edward Berg
2022-02-24	10-K	10.45	Asset Purchase Agreement, dated November 24, 2021, by and between Vaxart, Inc. and Kindred Biosciences, Inc.
2021-11-04	10-Q	10.4	Offer Letter, dated August 16, 2021, by and between the Company and James Cummings MD
2021-09-21	8-K	10.2	Second Amendment to Lease Agreement, dated September 17, 2021, by and between Vaxart, Inc. and Healthpeak Properties, Inc.
2021-09-21	8-K	10.1	Lease Agreement, dated September 17, 2021, by and between Vaxart, Inc. and Britannia Pointe Grand Limited Partnership.
2021-06-21	8-K	10.1	Vaxart, Inc. 2019 Equity Incentive Plan (as amended on April 28, 2021)
2021-02-25	10-K	10.40	Sublease Agreement dated November 16, 2020, by and between Vaxart, Inc. and Vera Therapeutics, Inc.
2020-11-12	10-Q	10.6	Statement of Work 004, dated September 11, 2020, under the Master Services Agreement, dated April 17, 2020, by and between Vaxart, Inc. and Kindred Biosciences, Inc.
2020-11-12	10-Q	10.5	Statement of Work 003, dated September 11, 2020, under the Master Services Agreement, dated April 17, 2020, by and between Vaxart, Inc. and Kindred Biosciences, Inc.
2020-11-12	10-Q	10.4	Master Services Agreement, dated April 17, 2020, by and between Vaxart, Inc. and Kindred Biosciences, Inc.
2020-06-15	8-K	10.2	Letter Agreement, dated June 14, 2020, between Vaxart, Inc. and Andrei Floroiu.
2020-06-15	8-K	10.1	Separation Agreement, dated June 14, 2020, between Vaxart, Inc. and Wouter W. Latour, M.D.
2020-05-12	10-Q	10.4	Letter dated December 27, 2018, from the Company to Margaret Echerd
2020-05-12	10-Q	10.3	Offer Letter, dated March 26, 2018, by and between the Company and Margaret Echerd
2020-05-12	10-Q	10.2	Offer Letter, dated May 1, 2006, by and between the Company and Dr. Sean Tucker
2020-03-02	8-K	10.1	Form of Securities Purchase Agreement, dated February 27, 2020, among the Company and the Purchasers named therein
2019-09-19	8-K	10.1	First Amendment to Lease Agreement dated September 17, 2019, by and between Vaxart, Inc. and HCP, Inc.
2019-04-24	8-K	10.3	Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Award Agreement under the 2019 Equity Incentive Plan.
2019-04-24	8-K	10.2	Form of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the 2019 Equity Incentive Plan.
2019-04-24	8-K	10.1	2019 Equity Incentive Plan.
2019-03-20	8-K	10.3	Form of Placement Warrants.
2019-03-20	8-K	10.2	Engagement Letter, dated as of January 25, 2019, by and between Vaxart, Inc. and H.C. Wainwright & Co., LLC., as amended.
2019-03-20	8-K	10.1	Form of Securities Purchase Agreement, dated as of March 19, 2019, by and among Vaxart, Inc. and the Purchasers named therein.
2018-08-10	10-Q	10.7	EXHBIT 10.7
2018-08-10	10-Q	10.6	EXHBIT 10.6
2018-08-10	10-Q	10.5	EXHBIT 10.5
2018-08-10	10-Q	10.4	EXHBIT 10.4
2018-08-10	10-Q	10.2	EXHBIT 10.2
2018-08-10	10-Q	10.1	EXHBIT 10.1
2018-06-06	8-K	10.1	Severance Benefit Plan and Form of Severance Benefit Plan Participation Notice.
2018-02-20	8-K	10.3	Form of Indemnification Agreement
2018-02-20	8-K	10.2	Warrant issued to Oxford Finance LLC, dated February 13, 2018
2018-02-20	8-K	10.1	Second Amendment to the Loan Agreement, dated February 13, 2018, between Vaxart, Inc. and Oxford Finance LLC
2018-02-09	8-K	10.1	Settlement Agreement, dated as of February 9, 2018, by and among Aviragen Therapeutics, Inc., Vaxart, Inc., Digirad Corporation and East Hill Management Company, LLC.
2017-05-08	10-Q	10.1	Employee Stock Option Grant Form
2016-04-26	8-K	10.2	Protective Rights Agreement between Aviragen Therapeutics, Inc. and HealthCare Royalty Partners III, L.P. dated April 22, 2016.
2016-04-26	8-K	10.1	Royalty Interest Acquisition Agreement by and between Aviragen Therapeutics, Inc., Biota Holdings Pty Ltd, Biota Scientific Management Pty. Ltd. and HealthCare Royalty Partners III, L.P. dated April 22, 2016.
2015-11-02	8-K	10.1	Executive Employment Agreement, effective as of November 2, 2015, between Biota Pharmaceuticals, Inc. and Mark Colonnese.
2015-10-02	8-K	10.1	At Market Issuance Sales Agreement, dated October 2, 2015, by and between Biota Pharmaceuticals, Inc., MLV & Co. LLC and FBR Capital Markets & Co.
2015-02-06	10-Q	10.18	Executive Employment Agreement, dated as October 1, 2014, between Biota Pharmaceuticals, Inc. and Russell H. Plumb
2015-02-06	10-Q	10.17	Executive Employment Agreement, dated as October 1, 2014, between Biota Pharmaceuticals, Inc. and Joseph M. Patti
2013-12-10	8-K	10.2	Form of Market-Based Stock Unit Award Agreement under the 2007 Omnibus Equity and Incentive Plan.
2013-12-10	8-K	10.1	Form of Employee Stock Option Agreement under the 2007 Omnibus Equity and Incentive Plan.
2013-11-27	8-K	10.1	Executive Employment Agreement, dated as of November 26, 2013, between Biota Pharmaceuticals, Inc., and Peter Azzarello.
2013-09-27	10-K	10.6	Research and License Agreement, dated February 21, 1990, by and among Biota Scientific Management Pty. Ltd., Biota Holdings Limited, Glaxo Australia Pty. Ltd. and Glaxo Group Limited.
2013-05-10	10-Q	10.9	Contract, dated March 31, 2011, between Biota Scientific Management Pty. Ltd. and Office of Biomedical Advanced Research and Development Authority within the Office of the Assistant Secretary for preparedness and Response at the U.S. Department of Health and Human Services.
2013-05-10	10-Q	10.8	Commercialization Agreement, dated March 27, 2009, between Biota Holdings Limited, Biota Scientific Management Pty. Ltd and Daiichi Sankyo Company, Ltd.
2013-05-10	10-Q	10.7	Amendment #2 to Collaboration and License Agreement, dated March 27, 2009, between Biota Holdings Limited, Biota Scientific Management Pty. Ltd. and Daiichi Sankyo Company, Limited.
2013-05-10	10-Q	10.6	Amendment #1 to Collaboration and License Agreement, dated June 30, 2005, between Biota Holdings Limited, Biota Scientific Management Pty. Ltd. and Sankyo Company, Ltd.
2013-05-10	10-Q	10.5	Collaboration and License Agreement, dated September 29, 2003, between Biota Holdings Limited and Sankyo Co., Ltd.
2013-05-06	8-K	10.1	Form of Indemnification Agreement for Directors and Executive Officers
2012-11-14	8-K	10.4	FORM OF LETTER AGREEMENT FOR STOCK OPTION GRANT
2012-11-14	8-K	10.3	FORM NON-PLAN STOCK UNITS AGREEMENT
2012-11-14	8-K	10.2	EXECUTIVE EMPLOYMENT AGREEMENT
2012-11-14	8-K	10.1	EXECUTIVE EMPLOYMENT AGREEMENT
2012-09-18	8-K	10.1	SUPPORT AGREEMENT
2011-03-22	8-K	10.3	AMENDMENT NO. 1 TO CHANGE OF CONTROL SEVERANCE AGREEMENT
2011-03-22	8-K	10.2	AMENDMENT NO. 1 TO CHANGE OF CONTROL SEVERANCE AGREEMENT
2011-03-22	8-K	10.1	AMENDED AND RESTATED EMPLOYMENT AGREEMENT
2009-11-05	10-Q	10.2	AGREEMENT BETWEEN NABI BIOPHARMACEUTICALS AND LINDA JENCKES
2009-05-06	10-Q	10.2	CHANGE OF CONTROL SEVERANCE AGREEMENT BETWEEN NABI BIO. AND MATTHEW KALNIK
2009-05-06	10-Q	10.1	EMPLOYMENT AGREEMENT BETWEEN NABI BIOPHARMACEUTICALS AND MATTHEW KALNIK, PH.D.
2009-03-11	10-K	10.28	CHANGE OF CONTROL SEVERANCE AGREEMENT

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Kalaris Therapeutics, Inc. (KLRS)	United States	$0.073B	-2.19
Atara Biotherapeutics, Inc. (ATRA)	United States	$0.086B	-6.48
Pelthos Therapeutics Inc. (PTHS)	United States	$0.086B	-1.20
CHAMPIONS ONCOLOGY, INC. (CSBR)	United States	$0.070B	-68.02
COGNITION THERAPEUTICS INC (CGTX)	United States	$0.090B	-6.52
BioStem Technologies, Inc. (BSEM)	United States	$0.069B
Eloxx Pharmaceuticals, Inc. (ELOX)	United States	$0.065B
MiNK Therapeutics, Inc. (INKT)	United States	$0.063B	-5.37
Cardiff Oncology, Inc. (CRDF)	United States	$0.101B	-2.22
EXOZYMES INC. (EXOZ)	United States	$0.058B